Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | esophageal cancer |
| ICD-0-3 | C15 |
| Methods | qPCR, Western blot etc |
| Sample | esophageal cancer and adjacent normal tissues,cell lines(Eca 109 and Kyse 150) |
| Expression Pattern | up-regulated |
| Function Description | Compared with no-tumor tissues, the LINC00152 expression was significantly increased in esophageal cancer tissues (P??.001). Compared with NC groups, the cell proliferation rate of lncRNA groups were significantly suppressed (P<0.05, respectively); the cell apoptosis and G1 phase rates were significantly enhanced in the lncRNA groups (P<0.05, respectively). In the proteins expressions, the EGFR, PI3K and AKT proteins expressions of lncRNA group were significantly inhibited and the P21 proteins expressions were significantly stimulated in the lncRNA groups compared with those of NC groups in Eca 109 and Kyse 150 cells. |
| Pubmed ID | 32190735 |
| Year | 2020 |
| Title | LINC00152 Knock-down Suppresses Esophageal Cancer by EGFR Signaling Pathway |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for esophageal cancer | OMIM COSMIC |